Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Ann S. LaCasce; R. Gregory Bociek; Ahmed Sawas; Paolo F Caimi; Edward Agura; Jeffrey Matous; Stephen M. Ansell; Howland E. Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A. O’Connor; Neil Josephson; Yinghui Wang; Ranjana Advani

doi:10.1182/BLOOD-2017-11-815183

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Ann S. LaCasce
, R. Gregory Bociek
, Ahmed Sawas
, Paolo F Caimi
, Edward Agura
, Jeffrey Matous
, Stephen M. Ansell
, Howland E. Crosswell
, Miguel Islas-Ohlmayer
, Caroline Behler
, Eric Cheung
, Andres Forero-Torres
, Julie Vose
, Owen A. O’Connor
, Neil Josephson
, Yinghui Wang
, Ranjana Advani

Harvard University
University of Nebraska Medical Center
Columbia University Medical Center
Seidman Cancer Center, University Hospitals, Cleveland, OH;
Charles A. Sammons Cancer Center, Dallas, TX;
Colorado Blood Cancer Institute, Denver, CO;
Mayo Clinic
St. Francis Hospital, Greenville, SC;
Jewish Hospital
Pacific Hematology Oncology Associates, San Francisco, CA;
The Oncology Institute of Hope & Innovation, Whittier, CA;
University of Alabama at Birmingham
Seattle Genetics
Stanford University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	132
Issue number	1
DOIs	https://doi.org/10.1182/BLOOD-2017-11-815183
State	Published - Jul 5 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD-2017-11-815183License: Unspecified

Cite this

LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P. F., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y., & Advani, R. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 132(1). https://doi.org/10.1182/BLOOD-2017-11-815183

LaCasce, AS, Bociek, RG, Sawas, A, Caimi, PF, Agura, E, Matous, J, Ansell, SM, Crosswell, HE, Islas-Ohlmayer, M, Behler, C, Cheung, E, Forero-Torres, A, Vose, J, O’Connor, OA, Josephson, N, Wang, Y & Advani, R 2018, 'Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.', Blood, vol. 132, no. 1. https://doi.org/10.1182/BLOOD-2017-11-815183

@article{554e153e449c4d00969a94d298aeec36,

title = "Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.",

author = "LaCasce, \{Ann S.\} and Bociek, \{R. Gregory\} and Ahmed Sawas and Caimi, \{Paolo F\} and Edward Agura and Jeffrey Matous and Ansell, \{Stephen M.\} and Crosswell, \{Howland E.\} and Miguel Islas-Ohlmayer and Caroline Behler and Eric Cheung and Andres Forero-Torres and Julie Vose and O{\textquoteright}Connor, \{Owen A.\} and Neil Josephson and Yinghui Wang and Ranjana Advani",

note = "Ann S. LaCasce, 1 R. Gregory Bociek, 2 Ahmed Sawas, 3 Paolo Caimi, 4 Edward Agura, 5 Jeffrey Matous, 6 Stephen M. Ansell, 7 Howland E. Crosswell, 8 Miguel Islas-Ohlmayer, 9 Caroline Behler, 10 Eric Cheung, 11 Andres Forero-Torres, 12 Julie Vose, 2 Owen A.",

year = "2018",

month = jul,

day = "5",

doi = "10.1182/BLOOD-2017-11-815183",

language = "American English",

volume = "132",

journal = "Blood",

publisher = "American Society of Hematology",

number = "1",

}

TY - JOUR

T1 - Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

AU - LaCasce, Ann S.

AU - Bociek, R. Gregory

AU - Sawas, Ahmed

AU - Caimi, Paolo F

AU - Agura, Edward

AU - Matous, Jeffrey

AU - Ansell, Stephen M.

AU - Crosswell, Howland E.

AU - Islas-Ohlmayer, Miguel

AU - Behler, Caroline

AU - Cheung, Eric

AU - Forero-Torres, Andres

AU - Vose, Julie

AU - O’Connor, Owen A.

AU - Josephson, Neil

AU - Wang, Yinghui

AU - Advani, Ranjana

N1 - Ann S. LaCasce, 1 R. Gregory Bociek, 2 Ahmed Sawas, 3 Paolo Caimi, 4 Edward Agura, 5 Jeffrey Matous, 6 Stephen M. Ansell, 7 Howland E. Crosswell, 8 Miguel Islas-Ohlmayer, 9 Caroline Behler, 10 Eric Cheung, 11 Andres Forero-Torres, 12 Julie Vose, 2 Owen A.

PY - 2018/7/5

Y1 - 2018/7/5

UR - http://europepmc.org/articles/PMC6073588

U2 - 10.1182/BLOOD-2017-11-815183

DO - 10.1182/BLOOD-2017-11-815183

M3 - Article

VL - 132

JO - Blood

JF - Blood

IS - 1

ER -

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Disciplines

Access to Document

Other files and links

Cite this